CN110862423B - 一种α-芳基半乳烯糖碳苷的合成方法及其在制药中的用途 - Google Patents
一种α-芳基半乳烯糖碳苷的合成方法及其在制药中的用途 Download PDFInfo
- Publication number
- CN110862423B CN110862423B CN201911096169.0A CN201911096169A CN110862423B CN 110862423 B CN110862423 B CN 110862423B CN 201911096169 A CN201911096169 A CN 201911096169A CN 110862423 B CN110862423 B CN 110862423B
- Authority
- CN
- China
- Prior art keywords
- aryl
- alpha
- galactosyl
- catalyst
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229910052799 carbon Inorganic materials 0.000 title claims abstract description 20
- 229930182470 glycoside Natural products 0.000 title claims abstract description 18
- 238000001308 synthesis method Methods 0.000 title description 4
- 238000006243 chemical reaction Methods 0.000 claims abstract description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000003054 catalyst Substances 0.000 claims abstract description 11
- 239000002904 solvent Substances 0.000 claims abstract description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 9
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000004327 boric acid Substances 0.000 claims abstract description 8
- 229940125904 compound 1 Drugs 0.000 claims abstract description 5
- 239000012074 organic phase Substances 0.000 claims abstract description 5
- 239000003208 petroleum Substances 0.000 claims abstract description 5
- 238000004440 column chromatography Methods 0.000 claims abstract description 4
- 239000012071 phase Substances 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims abstract description 4
- 239000012043 crude product Substances 0.000 claims abstract description 3
- 239000002994 raw material Substances 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims abstract 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- -1 o-methoxyphenyl Chemical group 0.000 claims description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 239000011998 white catalyst Substances 0.000 claims description 6
- SNNYSJNYZJXIFE-UHFFFAOYSA-L 2-(benzenesulfinyl)ethylsulfinylbenzene;palladium(2+);diacetate Chemical group [Pd+2].CC([O-])=O.CC([O-])=O.C=1C=CC=CC=1S(=O)CCS(=O)C1=CC=CC=C1 SNNYSJNYZJXIFE-UHFFFAOYSA-L 0.000 claims description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- KTQKOGBTMNDCFG-UHFFFAOYSA-N tert-butyl(diphenyl)silicon Chemical compound C=1C=CC=CC=1[Si](C(C)(C)C)C1=CC=CC=C1 KTQKOGBTMNDCFG-UHFFFAOYSA-N 0.000 claims 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 239000000047 product Substances 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 201000007270 liver cancer Diseases 0.000 abstract 1
- 208000014018 liver neoplasm Diseases 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
- 238000005481 NMR spectroscopy Methods 0.000 description 26
- 239000011734 sodium Substances 0.000 description 11
- 239000012230 colorless oil Substances 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- BIWQNIMLAISTBV-UHFFFAOYSA-N (4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C=C1 BIWQNIMLAISTBV-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 244000089409 Erythrina poeppigiana Species 0.000 description 2
- 235000009776 Rathbunia alamosensis Nutrition 0.000 description 2
- 229910004161 SiNa Inorganic materials 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- UWDMKTDPDJCJOP-UHFFFAOYSA-N 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-ium-4-carboxylate Chemical compound CC1(C)CC(O)(C(O)=O)CC(C)(C)N1 UWDMKTDPDJCJOP-UHFFFAOYSA-N 0.000 description 1
- 101100391174 Dictyostelium discoideum forC gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000003584 Ferrier rearrangement reaction Methods 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- UGJBHEZMOKVTIM-UHFFFAOYSA-N N-formylglycine Chemical group OC(=O)CNC=O UGJBHEZMOKVTIM-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 150000001975 deuterium Chemical group 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 238000007344 nucleophilic reaction Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- LOAUVZALPPNFOQ-UHFFFAOYSA-N quinaldic acid Chemical class C1=CC=CC2=NC(C(=O)O)=CC=C21 LOAUVZALPPNFOQ-UHFFFAOYSA-N 0.000 description 1
- 238000006462 rearrangement reaction Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
技术领域
本发明主要关于一种α-芳基半乳烯糖碳苷的合成方法及其在制药中的用途
背景技术
糖类广泛存在于自然界与生物体中,它与蛋白质、核酸共同构成了动植物体内最重要的生命物质。糖化学在生命科学与药物开发中均占据着极其重要的地位。碳糖苷比对应的氧糖苷对酸和酶更稳定,因此具有更长的生物半衰期,对于先导化合物的发现具有独特的优势碳苷已被发现具有多种药理活性,例如,抗肿瘤活性、抗病毒和抗菌活性等。
碳糖苷相对于氧糖苷合成更具挑战性,首先一般碳的亲核性比氧弱,难以参与亲核反应;其次,碳不属于异头原子,异头效应大幅度减弱,难以辅助产生高立体选择性。碳糖苷的立体选择性合成仍然是糖化学家的研究热点和难点之一,急需解决。已报道的碳苷合成方法有Ferrier重排反应,但是其通常需要使用当量的活化剂。新加坡的刘学伟小组曾报道使用催化量的催化剂介导分子内的重排反应产生碳糖苷,而此方法需要额外的步骤预先组装糖受体到烯糖3号位。本专利旨在通过采用3,4-O-碳酸酯烯糖供体在温和的条件下立体选择性地获得α-碳苷,开发其作为抗肿瘤药物的用途。
发明内容
针对上述技术问题,本发明提供一种α-芳基半乳烯糖碳苷化合物,及其制备方法和新用途。
一种α-芳基半乳烯糖碳苷化合物,结构式为:其中,PG包括硅基、烷基(C1-C4烷基或者苄基)、芳基(包括苯基,三苯基甲基,吡啶基等)和酯基(苯甲酸酯,吡啶酸酯,喹啉甲酸酯等);所述的R包括苯基及其衍生物、萘基及其衍生物、蒽及其衍生物。
作为优选方案,所述的PG为叔丁基二苯基氯硅烷,R2为对甲苯。
α-芳基半乳烯糖碳苷化合物的制备方法,具体是将催化剂,糖受体硼酸试剂和化合物1中加入溶剂中,在室温条件下进行搅拌反应,TLC检测反应进程,原料完全消失后,终止反应,萃取收集有机相,减压蒸馏除去溶剂得到粗产物,然后采用石油醚/乙酸乙酯溶液作为流动相进行柱层析获得α-芳基半乳烯糖碳苷,反应式如下
所述的化合物1、糖受体硼酸试剂、催化剂的摩尔量之比为1:1.2-2.5:0.01-0.1。
所述的催化剂包括White催化剂或Pd(OAc)2。
所述的溶剂包括四氢呋喃、乙醚、1,4-二氧六环、二氯甲烷、乙腈、N,N-二甲基甲酰胺、二甲基亚砜中的任意一种。
所述的糖受体硼酸试剂为对甲苯硼酸。
作为优选方案,本发明采用3,4-O-环碳酸酯烯糖与对甲基苯硼酸反应进行条件优化,发现醋酸钯在无水无氧条件下可以以94%的产率获得目标产物2,继续筛选不同的溶剂,产率都没有THF高,继续筛选不同的催化剂发现White催化剂可以在非无水无氧的条件下催化反应且产率可以达到95%,醋酸钯也可以催化但是产率下降到60%,零价钯催化剂Pd2(dba)3和Pd(PPh3)4都不能催化原料发生反应如下表所示。因此最优的反应条件是采用White催化剂在室温非无水无氧条件下室温反应。
反应用量0.1mmol的化合物1,0.2mmol的对甲苯硼酸,5mol%的钯催化剂,2mL溶剂,N.R.表示未反应。
附图说明
图1为化合物3的氢谱图。
图2为化合物3的碳谱图。
具体实施方式
实验试剂
White催化剂(96%,日本东京化成工业株式会社TCI)、石油醚(沸程60-90℃,天津市恒兴化学试剂制造有限公司)、乙酸乙酯(分析纯,天津市科密欧化学试剂有限司)、无水硫酸钠(分析纯,国药集团化学试剂有限公司)、氘代氯仿-d(氘原子含量99.8%,TMS含量0.03%V/V,10*0.5mL/盒,瑞士ARMAR公司);核磁管(5mm 100/pk 2ST500-8,美国Norell公司)。
实验仪器
ZXZ-4型旋片式真空泵(临海市谭氏真空设备有限公司)、DZF-6020型真空干燥箱(上海新苗医疗器械制造有限公司)、SHB-IIIA循环水式多用途真空泵(上海豫康科教仪器设备有限公司)、CL-4型平板磁力搅拌器(郑州长城科工贸有限公司)、EYELA SB-1100旋转蒸发仪(上海爱朗仪器有限公司)、FA2104B分析天平(上海越平科技仪器有限公司)、XRC-1型微熔点测定仪(四川大学科仪厂)、DF-101S集热式恒温加热磁力搅拌器(巩义市英峪予华仪器厂)、GZX-9240MBE数显鼓风干燥箱(上海博迅实业有限公司医疗设备厂)、ZF-6型三用紫外分析仪(上海嘉鹏科技有限公司)、Ultrashied 400MHz Plus核磁共振仪(瑞士Bruker公司)、API 4000LC-MS/MS质谱仪(德国布鲁克道尔顿公司)目标分子的合成
将二乙酸-1,2-双(苯亚磺酰)乙基钯(II)(White催化剂,4.6mg,0.005mmol)和3,4-O-碳酸酯半乳烯糖1(0.1mmol)加入2mL的THF和糖受体硼酸试剂(0.2mmol)。无需严格无水无氧条件,室温搅拌,TLC检测反应进程,直到原料完全消失,终止反应,萃取或者有机相干燥得到粗产物,最后采用石油醚/乙酸乙酯溶液作为流动相进行柱层析获得4-羟基-2,3-不饱和碳苷。合成方法如下:
目标分子清单:
2.3碳糖苷产物分析与鉴定表征
(1S)-1,5-anhydro-2,3-dideoxy-6-O-(tert-butyldiphenylsilyl)-1-C-tolyl-D-threo-hex-2-enitol(3)
无色油状物;产率95%;1H NMR(400MHz,CD3CN)δ7.68–7.57(m,4H),7.45–7.38(m,2H),7.37–7.32(m,4H),7.30–7.25(m,2H),7.15(d,J=7.8Hz,2H),6.32–6.20(m,2H),5.31(d,J=2.7Hz,1H),3.95–3.89(m,1H),3.89–3.80(m,2H),3.71(td,J=6.2,2.1Hz,1H),2.37(s,3H),1.95(d,J=9.0Hz,1H),1.02(s,9H);13C NMR(101MHz,CDCl3)δ137.6,136.1,135.8,135.7,133.5,133.4,131.6,129.8,129.7,129.2,127.9,127.8,127.7,74.1,72.3,63.9,62.6,27.0,21.3,19.3;HRMS(ESI)m/z:calcd.forC29H34O3Si(M+Na)+481.2179,found481.2175;[α]D 20=-128.3(c=1.0,CHCl3).
(1S)-1,5-anhydro-2,3-dideoxy-6-O-(tert-butyldiphenylsilyl)-1-C-(2-methoxyphenl)-D-threo-hex-2-enitol(4)
无色油状物;产率71%;1H NMR(500MHz,CDCl3)δ7.62(ddt,J=9.5,6.7,1.5Hz,4H),7.44–7.37(m,2H),7.33(qd,J=7.7,7.0,1.4Hz,6H),6.97–6.86(m,2H),6.24(ddd,J=10.1,5.4,2.1Hz,1H),6.17(dd,J=10.2,3.4Hz,1H),5.72(dd,J=3.3,2.2Hz,1H),3.96(d,J=5.2Hz,1H),3.94–3.80(m,6H),1.87(s,1H),1.00(s,9H);13C NMR(126MHz,CDCl3)δ157.7,135.8,135.7,133.6,133.6,131.8,129.7,129.7,129.5,128.6,127.8,127.7,126.4,120.0,111.0,72.7,69.9,63.8,62.7,55.7,26.9,19.2;HRMS(ESI)m/z:calcd.forC29H34O4Si(M+Na)+497.2124,found 497.2127;[α]D 20=-97.4(c=1.0,CHCl3)..
(1S)-1,5-anhydro-2,3-dideoxy-6-O-(tert-butyldiphenylsilyl)-1-C-(p-Methoxyphenyl)-D-threo-hex-2-enitol(5)
无色油状物;产率95%;1H NMR(400MHz,CDCl3)δ7.62(dt,J=7.8,1.3Hz,4H),7.44–7.37(m,2H),7.37–7.29(m,6H),6.87(d,J=8.4Hz,2H),6.23(q,J=1.2Hz,2H),5.29(s,1H),3.97–3.89(m,1H),3.88–3.83(m,1H),3.82(d,J=1.0Hz,3H),3.82–3.78(m,1H),3.67(td,J=6.2,1.9Hz,1H),1.97(d,J=8.7Hz,1H),1.02(s,9H);13C NMR(101MHz,CDCl3)δ159.4,135.8,135.7,133.5,133.4,131.7,131.1,129.8,129.8,129.4,127.8,127.8,113.8,73.9,72.1,63.8,62.6,55.4,26.9,19.3;HRMS(ESI)m/z:calcd.for C29H34O4Si(M+Na)+497.2124,found 497.2127;[α]D 20=-95.4(c=1.0,CHCl3).
(1S)-1,5-anhydro-2,3-dideoxy-6-O-(tert-butyldiphenylsilyl)-1-C-phenyl-D-threo-hex-2-enitol(6)
无色油状物;产率90%;1H NMR(500MHz,CDCl3)δ7.63(ddd,J=8.2,4.7,1.5Hz,4H),7.43–7.28(m,12H),6.33–6.19(m,2H),5.35(t,J=2.5Hz,1H),3.91(d,J=8.1Hz,1H),3.90–3.82(m,2H),3.71(td,J=6.2,2.1Hz,1H),1.96(s,1H),1.03(s,9H);13C NMR(126MHz,CDCl3)δ139.2,135.8,135.7,133.5,133.4,131.5,129.8,129.8,128.5,127.9,127.9,127.8,127.8,74.2,72.6,63.9,62.6,26.9,19.3;HRMS(ESI)m/z:calcd.for C28H32O3Si(M+Na)+467.2018,found 467.2022;[α]D 20=-147.7(c=1.0,CHCl3).
(1S)-1,5-anhydro-2,3-dideoxy-6-O-(tert-butyldiphenylsilyl)-1-C-(4-(4-methoxybenzyl)phenyl)-D-threo-hex-2-enitol(7)
无色油状物;产率70%;1H NMR(500MHz,CDCl3)1H NMR(500MHz,CDCl3)δ7.62(ddd,J=7.9,3.2,1.4Hz,4H),7.42–7.29(m,10H),6.96–6.89(m,4H),6.23(d,J=2.8Hz,2H),5.28(s,1H),5.00(s,2H),3.91(dt,J=8.9,2.3Hz,1H),3.89–3.83(m,1H),3.82(s,3H),3.80–3.78(m,1H),3.67(td,J=6.1,2.0Hz,1H),1.94(d,J=9.0Hz,1H),1.01(s,9H);13CNMR(126MHz,CDCl3)δ159.6,158.7,135.8,135.7,133.5,133.4,131.7,131.3,129.8,129.8,129.4,129.3,129.1,127.8,114.8,114.2,73.9,72.1,70.0,63.8,62.6,55.5,26.9,19.3;HRMS(ESI)m/z:calcd.for C36H40O4SiNa(M+Na)+587.2594,found 587.2585;[α]D 20=-107.2(c=1.0,CHCl3).
(1S)-1,5-anhydro-2,3-dideoxy-6-O-(tert-butyldiphenylsilyl)-1-C-(o-tolyl)-D-threo-hex-2-enitol(8)
白色固体;产率70%;1H NMR(400MHz,CDCl3)δ7.57(ddd,J=8.1,5.0,1.5Hz,4H),7.42–7.35(m,2H),7.31(t,J=7.3Hz,4H),7.25–7.14(m,3H),6.37–6.29(m,1H),6.15(dd,J=10.2,3.6Hz,1H),5.51(dd,J=3.7,2.0Hz,1H),4.03–3.93(m,1H),3.87–3.72(m,2H),3.61(td,J=6.1,2.0Hz,1H),2.46(s,3H),2.06(d,J=8.5Hz,1H),0.96(s,9H);1.01(s,9H);13C NMR(101MHz,CDCl3)δ138.8,135.9,135.7,135.6,133.5,133.4,131.8,131.2,129.8,129.8,128.5,128.5,128.5,127.8,125.1,77.5,77.2,76.8,72.4,71.9,63.9,63.0,26.9,19.4,19.2;HRMS(ESI)m/z:calcd.for C29H34O3Si(M+Na)+481.2175,found 481.2180;[α]D 20=-12.8(c=0.6,CHCl3).
(1S)-1,5-anhydro-2,3-dideoxy-6-O-(tert-butyldiphenylsilyl)-1-C-(3,5-dimethyl-phenyl)-D-threo-hex-2-enitol(9)
无色油状物;产率90%;1H NMR(400MHz,CDCl3)δ7.63(ddd,J=8.1,4.6,1.5
Hz,4H),7.45–7.30(m,6H),6.98(s,2H),6.96(s,1H),6.30–6.19(m,2H),5.27(s,1H),4.01–3.92(m,1H),3.92–3.80(m,2H),3.73(td,J=6.2,2.2Hz,1H),2.31(s,6H),1.99(d,J=8.8Hz,1H),1.01(s,9H);13C NMR(101MHz,CDCl3)δ138.9,138.0,135.8,135.7,133.5,133.5,131.7,129.8,129.8,129.7,127.8,127.7,125.9,74.3,72.2,63.8,62.6,26.9,21.5,19.3;HRMS(ESI)m/z:calcd.for C30H36O3Si(M+Na)+495.2331,found 495.2331;[α]D 20=-122.9(c=1.0,CHCl3).
(1S)-1,5-anhydro-2,3-dideoxy-6-O-(tert-butyldiphenylsilyl)-1-C-(naphthalen-2-yl)-D-threo-hex-2-enitol(10)
无色油状物;产率92%;1H NMR(400MHz,CDCl3)δ7.89–7.76(m,3H),7.73(d,J=1.6Hz,1H),7.62–7.53(m,5H),7.54–7.48(m,2H),7.39–7.27(m,3H),7.29–7.19(m,3H),6.40(dd,J=10.2,3.5Hz,1H),6.32(ddd,J=10.2,5.2,1.8Hz,1H),5.52–5.45(m,1H),3.96(ddd,J=8.8,5.2,2.1Hz,1H),3.87(qd,J=10.7,6.2Hz,2H),3.68(td,J=6.2,2.1Hz,1H),2.02(d,J=8.9Hz,1H),1.00(s,9H);13C NMR(101MHz,CDCl3)δ136.5,135.7,135.6,133.4,133.4,133.1,133.1,131.4,129.8,129.7,128.4,128.3,128.3,127.8,127.7,126.8,126.3,126.3,126.3,74.3,72.3,63.8,62.6,26.9,19.3;HRMS(ESI)m/z:calcd.forC32H34O3SiNa(M+Na)+517.2175,found 517.2194;[α]D 20=-167.2(c=0.47,CHCl3).
(1S)-1,5-anhydro-2,3-dideoxy-6-O-(tert-butyldiphenylsilyl)-1-C-(4-(trifluoromethyl)phenyl)-D-threo-hex-2-enitol(11)
无色油状物;产率64%;1H NMR(500MHz,CDCl3)1H NMR(500MHz,Chloroform-d)δ7.66–7.61(m,4H),7.58(d,J=8.2Hz,3H),7.51(d,J=8.1Hz,3H),7.41(tdd,J=6.1,3.9,2.0Hz,2H),7.39–7.30(m,4H),6.35–6.20(m,2H),5.36(d,J=2.1Hz,1H),3.89(ddd,J=14.6,6.8,2.9Hz,3H),3.59(td,J=6.1,2.1Hz,1H),1.93(d,J=9.0Hz,1H),1.03(s,9H);13CNMR(126MHz,CDCl3)δ143.4,135.7,135.7,133.4,133.3,130.6,129.9,129.9,128.5,127.9,127.8,127.8,125.5,125.5,125.4,125.4,77.4,73.4,73.1,63.8,62.4,26.9,19.3;HRMS(ESI)m/z:calcd.for C29H31F3O3Si(M+Na)+535.1982,found 535.1907;[α]D 21=-114.1(c=0.73,CHCl3).
(1S)-1,5-anhydro-2,3-dideoxy-6-O-(tert-butyldiphenylsilyl)-1-C-(4-(hydroxymethyl)phenyl)-D-threo-hex-2-enitol(12)
无色油状物;产率64%;1H NMR(400MHz,CDCl3)δ7.63(dq,J=6.7,1.4Hz,4H),7.43–7.30(m,10H),6.32–6.20(m,2H),5.34(s,1H),4.71(s,2H),3.91(d,J=8.0Hz,1H),3.89–3.81(m,2H),3.69(td,J=6.1,2.1Hz,1H),1.94(d,J=9.0Hz,1H),1.02(s,9H);13CNMR(126MHz,CDCl3)δ140.5,138.6,135.8,135.7,135.7,133.4,133.4,131.4,129.8,129.8,128.1,127.9,127.8,127.2,73.9,72.5,65.2,63.9,62.6,26.9,19.3;HRMS(ESI)m/z:calcd.for C29H34O4Si(M+Na)+497.2124,found497.2133;[α]D 21=-42.1(c=0.56,CHCl3).
(1S)-1,5-anhydro-2,3-dideoxy-6-O-methyl-1-C-(p-tolyl)-D-threo-hex-2-enitol(13)
无色油状物;产率89%;1H NMR(400MHz,CDCl3)δ7.36–7.26(m,2H),7.16(d,J=7.7Hz,2H),6.24(t,J=4.6Hz,2H),5.32(s,1H),3.92(d,J=8.1Hz,1H),3.76(td,J=5.8,2.3Hz,1H),3.68–3.55(m,1H),3.33(s,3H),2.34(s,3H),2.20(d,J=8.6Hz,1H);13C NMR(101MHz,CDCl3)δ137.9,135.7,131.5,129.2,128.1,127.7,74.3,72.5,70.2,63.0,59.4,21.3;HRMS(ESI)m/z:calcd.for C14H18O3(M+Na)+257.1154,found 257.156;[α]D 21=-248.4(c=0.59,CHCl3)。
Claims (4)
2.根据权利要求1所述的α-芳基半乳烯糖碳苷化合物的制备方法,其特征在于,化合物1、糖受体硼酸试剂、催化剂的摩尔量之比为1:1.2-2.5:0.01-0.1。
3.根据权利要求1所述的α-芳基半乳烯糖碳苷化合物的制备方法,其特征在于,所述的溶剂为四氢呋喃、乙腈、N,N-二甲基甲酰胺中的任意一种。
4.根据权利要求1所述的α-芳基半乳烯糖碳苷化合物的制备方法,其特征在于,所述的糖受体硼酸试剂为对甲苯硼酸。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911096169.0A CN110862423B (zh) | 2019-11-11 | 2019-11-11 | 一种α-芳基半乳烯糖碳苷的合成方法及其在制药中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911096169.0A CN110862423B (zh) | 2019-11-11 | 2019-11-11 | 一种α-芳基半乳烯糖碳苷的合成方法及其在制药中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110862423A CN110862423A (zh) | 2020-03-06 |
CN110862423B true CN110862423B (zh) | 2023-05-02 |
Family
ID=69653896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911096169.0A Active CN110862423B (zh) | 2019-11-11 | 2019-11-11 | 一种α-芳基半乳烯糖碳苷的合成方法及其在制药中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110862423B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111978278B (zh) * | 2020-08-18 | 2022-07-15 | 三峡大学 | 一类2,3-不饱和糖氧苷类化合物的合成方法 |
CN113603730B (zh) * | 2021-08-31 | 2023-05-02 | 三峡大学 | 硼酸三酯为糖受体选择性合成氧糖苷或2-脱氧糖的方法 |
CN113929650B (zh) * | 2021-10-11 | 2023-08-01 | 三峡大学 | 一类2,3-不饱和糖碳苷类化合物的合成方法 |
-
2019
- 2019-11-11 CN CN201911096169.0A patent/CN110862423B/zh active Active
Non-Patent Citations (1)
Title |
---|
Mengnan Lai et al..Open-Air Stereoselective Construction ofC‑Aryl Glycosides.《Organic Letters》.2020, * |
Also Published As
Publication number | Publication date |
---|---|
CN110862423A (zh) | 2020-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110862423B (zh) | 一种α-芳基半乳烯糖碳苷的合成方法及其在制药中的用途 | |
CN104370755A (zh) | 一种光学活性的3-氨基丁醇和3-氨基丁酸的制备方法 | |
CN101186625B (zh) | 亚乙撑双二茂铁衍生物及合成方法 | |
CN112321627A (zh) | 一种轴手性芳乙炔基硅烷化合物及其制备方法 | |
CN109761984B (zh) | 不对称氢转移合成手性五元碳环嘌呤核苷的方法 | |
CN113105468B (zh) | 一种含苯并吡喃酮的多环螺吲哚酮类化合物及其制备方法和应用 | |
Ito et al. | An Improved Procedure for Aryne Generation from o‐Triazenylarylboronic Acids through One‐Pot Boronate Formation/Silica Gel Treatment | |
CN111995638B (zh) | 一类3-硫-1-烯糖类化合物的合成方法 | |
CN113735756B (zh) | 铑催化合成手性3,3-二取代异吲哚啉酮类化合物的方法 | |
Rončák et al. | Novel carbohydrate-based thioureas as organocatalysts for asymmetric Michael addition of 1, 3-dicarbonyl compounds to nitroolefins | |
CN105859718A (zh) | 一种铜催化的含氮多杂环化合物的制备方法 | |
CN105384715B (zh) | 一种7-位取代的3-溴-4-苯基香豆素系列化合物制备方法 | |
CN111205261B (zh) | 一种合成萘并吡喃-2-酮类化合物的方法 | |
CN100588656C (zh) | 钳形双咪唑啉钯化合物及其在Suzuki反应中的应用 | |
CN105693627B (zh) | 一种手性三元碳环嘧啶核苷类似物及其制备方法 | |
CN108383754B (zh) | 一类芳基肟脂化合物的制备方法和应用 | |
CN113372353A (zh) | 一种二氟烷基化的二氢呋喃喹啉酮衍生物及其制备方法 | |
CN108822072B (zh) | 一种制备伊力格鲁司他的方法 | |
CN107827890A (zh) | 通过嘌呤、醛和酸酐的动态动力学拆分合成手性嘌呤非环核苷的方法 | |
JP2005247715A (ja) | 配位子の合成方法 | |
CN113429424B (zh) | 一种[1,2,4]噁二嗪并吲哚啉-3-酮衍生物的制备方法 | |
CN111943888B (zh) | 1-芳基异喹啉化合物及其合成方法 | |
JP6893360B2 (ja) | 1,1’−ビナフチル誘導体の製造方法および1,1’−ビナフチル誘導体 | |
CN117164506A (zh) | 一种茚并[1,2-b]吲哚-10(5H)-酮化合物的制备方法 | |
CN118005551A (zh) | 一种具有抗癌活性天然产物Talaroconvolutin A的合成工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230904 Address after: Room F504, Guangzhou International Business Incubator, No. 3 Ranyue Road, Science City, Huangpu District, Guangzhou City, Guangdong Province, 510000 Patentee after: Guangzhou Younan Technology Co.,Ltd. Address before: 443002 No. 8, University Road, Xiling District, Yichang, Hubei Patentee before: CHINA THREE GORGES University |
|
TR01 | Transfer of patent right |